Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3086-3092

  Mushtaq, Shazad ^a   Ge, Yigong ^b   Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Peninsula Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

AMPC GENE; ARTICLE; BACTERIUM ISOLATION; DRUG ACTIVITY; DRUG ISOLATION; GENE MUTATION; IN VITRO STUDY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; ONCOGENE; OPRD GENE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TRANSMISSION ELECTRON MICROSCOPY;

BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CONJUGATION, GENETIC; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENES, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 3342905057     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3086-3092.2004     Document Type: Article

References (24)

1. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
2. Chart, H. 1994. Sodium dodecyl sulfate polyacrylamide gel electrophoresis for the separation and resolution of bacterial components, p. 21-33. In H. Chart (ed.), Methods in practical laboratory methodology, CRC Press, Inc., Boca Raton, Fla.
3. Chen, H. Y., and D. M. Livermore. 1994. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J. Antimicrob. Chemother. 33:949-958.
4. Danel, F., L. M. Hall, D. Gur, H. E. Akalin, and D. M. Livermore. 1995. Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 35:281-294.
5. Danel, F., L. M. Hall, D. Gur, and D. M. Livermore. 1995. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1881-1884.
6. Danel, F., L. M. Hall, D. Gur, and D. M. Livermore. 1998. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob. Agents Chemother. 42:3117-3122.
7. Danel, F., L. M. Hall, and D. M. Livermore. 1999. Laboratory mutants of OXA-10 β-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 43:339-344.
8. Hall, L. M., D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin. 1993. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:1637-1644.
9. Kohler, T., M. Michea-Hamzehpour, S. F. Epp, and J. C. Pechere. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43:424-427.
10. Li, X. Z., D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38:1732-1741.
11. Li, X. Z., D. Ma, D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 38:1742-1752.
12. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.
13. Livermore, D. M. 1984. Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and -susceptible strains of Pseudomonas aeruginosa. J. Med. Microbiol. 18:261-270.
14. Livermore, D. M. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046-2048.
15. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
16. Livermore, D. M. 2002. The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investig. Drugs 3:218-224.
17. Livermore, D. M., and H. Y. Chen. 1997. Potentiation of β-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases. J. Antimicrob. Chemother. 40:335-343.
18. Livermore, D. M., R. J. Williams, and J. D. Williams. 1981. In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other gram-negative organisms and its stability to their β-lactamases. J. Antimicrob. Chemother. 8:355-362.
19. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
20. National Committee for Clinical Laboratory Standards. 2003. Methods of dilution antimicrobial susceptibility testing of bacteria that grow aerobically, M07-A6. Approved standard, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Nikaido, H. 1998. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin. Infect. Dis. 27(Suppl. 1):S32-S41.
22. Nordmann, P., and L. Poirel. 2002. Emerging carbapenemases in gram-negative aerobes. Clin. Microbiol. Infect. 8:321-331.
23. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:94-99.
24. Yang, Y. J., and D. M. Livermore. 1989. Interactions of meropenem with class I chromosomal β-lactamases. J. Antimicrob. Chemother. 24(Suppl. A): 207-217.